Browse the corpus

Acute Coronary Syndrome (ACS) catheter interventions, primarily percutaneous coronary intervention, are life-saving procedures aimed at restoring coronary blood flow in patients with unstable angina and myocardial infarctions. These interventions involve mechanical revascularization through balloon angioplasty and stent placement to alleviate myocardial ischemia and prevent infarct progression. Rapid diagnosis, prompt reperfusion, and evidence-based pharmacologic support—such as antiplatelet and anticoagulant therapy—are essential for optimizing outcomes. The success of these interventions relies on a coordinated, multidisciplinary approach involving cardiologists, nurses, advanced clinicians, and pharmacists to ensure patient safety, minimize complications, and promote long-term cardiovascular health. Clinicians participating in this course deepen their understanding of the pathophysiology, indications, and procedural techniques associated with ACS catheter interventions. They gain practical insights into pre-, intra-, and postprocedural management, including hemodynamic monitoring, medication optimization, and prevention of complications such as stent thrombosis or bleeding. The course emphasizes interprofessional collaboration, evidence-based decision-making, and patient education strategies to enhance care coordination and outcomes. By mastering these competencies, participants enhance their ability to deliver high-quality, patient-centered cardiovascular care, ultimately improving survival and recovery rates in patients with acute coronary syndromes. Objectives: Determine the appropriate use of adjunctive imaging modalities—such as intravascular ultrasound and optical coherence tomography—to optimize stent deployment and lesion assessment. Compare outcomes between emergent and elective percutaneous coronary intervention, as well as radial versus femoral access, to determine optimal procedural strategy. Identify the differences between a diagnostic catheter, a guiding catheter, a monorail balloon catheter, and an over-the-wire balloon catheter. Collaborate and communicate effectively within the interprofessional healthcare team—including interventional cardiologists, nurses, pharmacists, and rehabilitation specialists—to ensure coordinated care, optimize clinical outcomes, and reduce hospital readmissions. Access free multiple choice questions on this topic.

Acute coronary syndrome (ACS) is among the most common diseases clinicians encounter in the inpatient setting. This syndrome comprises a spectrum of obstructive coronary artery disease that most commonly results from plaque rupture or erosion, exposing the lipid-rich core to the circulation and triggering platelet activation and the coagulation cascade, which leads to acute thrombotic occlusion.[1] Each stage of this syndrome can be treated differently based on clinical presentation, but a catheter-based interventional approach is often preferred. For years, the primary treatment of ACS revolved around maximizing medical therapy with the use of antiplatelet and anticoagulation therapy, antianginal medications, and aggressive lipid-lowering and risk factor modification.[1] In 1958, the advent of thrombolytics shifted the paradigm in the approach and treatment of ACS. First used by Fletcher and colleagues and later validated by trials such as ISIS, GUSTO, and GISSI, intravenous thrombolytic therapy has been shown to successfully treat acute thrombotic occlusions, particularly in ST-elevated myocardial infarctions.[2] However, even with the improvement in survival, size of the infarct, and overall morbidity, thrombolytic therapy continued to demonstrate major bleeding issues, including intracranial hemorrhage, as well as issues with reinfarction. The most effective thrombolytic regimens achieve angiographic infarct-artery patency in only 50% of patients within 90 minutes. Bleeding requiring transfusion occurs in 5% of patients and stroke in 1.8% with these regimens.[3] The management of ACS showed a gradual improvement; however, outcomes remained poor due to these issues. This all changed in 1977, when Andreas Gruentzig developed a novel approach to treat ACS using balloon angioplasty, forever changing the landscape of cardiology; he would later be known as the father of interventional cardiology.[4]

Catheter-based interventions were first established in the late 1970s. The idea behind catheter-directed interventions for ACS flourished due to its ability to use the circulation as a "vascular freeway" to approach occlusive coronary disease without the use of open-heart surgery. The ability to gain percutaneous vascular access and intervene on an occluded vessel with a catheter completely revolutionized cardiovascular medicine. A cardiac catheter, first described by Werner Forssmann in 1929, is a plastic tube that allows the delivery of substances (medications or contrast agents) for the imaging and monitoring of intracardiac pressures. Catheters evolved from purely diagnostic pressure-measurement tools to therapeutic devices, as described by Gruentzig's breakthrough in the late 1970s. Throughout the 1970s and 1980s, balloon angioplasty remained a controversial procedure and was primarily indicated for stable ischemic heart disease lesions. Individuals with ACS continued to rely on the use of intravenous thrombolytic therapy and coronary artery bypass grafting (CABG) surgery for treatment. Then, in the late 1990s, Stone and Grines, in collaboration with the other primary angioplasty in myocardial infarction (PAMI) investigators, demonstrated the safety and efficacy of balloon angioplasty as the primary treatment for ACS. PAMI shown that patients that presented with ACS treated with percutaneous balloon angioplasty compared to tissue plasminogen activator (t-PA) demonstrated reduced rates of in-hospital mortality (2% vs 7%, P = 0.03), as well as recurrent ischemia (11% vs 29%, P < 0.001) and stroke (0% vs 4%, P = 0.02), and demonstrated shorter hospital stays (7.6 vs 8.4 d, P = 0.04).[5]

Throughout the 1970s and 1980s, balloon angioplasty remained a controversial procedure and was primarily indicated for stable ischemic heart disease lesions. Individuals with ACS continued to rely on the use of intravenous thrombolytic therapy and coronary artery bypass grafting (CABG) surgery for treatment. Then, in the late 1990s, Stone and Grines, in collaboration with the other primary angioplasty in myocardial infarction (PAMI) investigators, demonstrated the safety and efficacy of balloon angioplasty as the primary treatment for ACS. PAMI shown that patients that presented with ACS treated with percutaneous balloon angioplasty compared to tissue plasminogen activator (t-PA) demonstrated reduced rates of in-hospital mortality (2% vs 7%, P = 0.03), as well as recurrent ischemia (11% vs 29%, P < 0.001) and stroke (0% vs 4%, P = 0.02), and demonstrated shorter hospital stays (7.6 vs 8.4 d, P = 0.04).[5] Again, in the late 1990s, 2 more landmark trials, BENESTENT and STRESS, were published, demonstrating that a metal scaffold, termed a stent, was efficacious and safe for implantation in coronary arteries and had a lower rate of major cardiovascular adverse events compared with balloon angioplasty.[6] These stents, however, were bulky, prone to restenosis, and required repeat revascularization. Additionally, the procedure itself correlated with many vascular complications, limiting its utility and widespread adoption. These issues were addressed in the early 2000s with the development of a new stent design capable of eluting antiproliferative agents (eg, sirolimus, paclitaxel).[7] This discovery once again revolutionized cardiology, enabling the treatment of both stable ischemic heart disease and ACS. As time has progressed, the catheter and catheter delivery system designs have undergone a variety of changes, allowing for greater capabilities, such as the delivery of equipment, such as stents and balloons, over a wire or monorail system, as well as improved deliverability to target vessels with lower rates of major adverse cardiovascular events.

ACS is consistently a leading global cause of morbidity and mortality. In the United States (US), the estimated annual incidence of ACS is approximately 550,000 new events and more than 200,000 recurrent cases. ACS primarily affects adults and varies by sex, occurring more frequently and at an earlier age in men than in women, with mean onset ages of 65 years for men and 72 years for women.[8] According to the National Cardiovascular Data Registry (NCDR), over 600,000 percutaneous coronary interventions are performed annually in the US. In 2014, the registry reported 667,424 procedures performed in 1612 hospitals across the US. Additionally, NCDR reports that in 2014, approximately 64% of procedures were for ACS.[9]

ACS comprises a spectrum of obstructive coronary artery disease that most commonly arises from plaque rupture and/or erosion, leaving the vulnerable lipid-rich core exposed to the circulation and activating platelets and the coagulation cascade, leading to acute thrombotic occlusion. There are 3 major subtypes of ACS: unstable angina, non-ST elevation myocardial infarction (NSTEMI), and STEMI. Each of these subtypes represents a different stage in the disease spectrum. Plaque erosion with subendocardial ischemia represents the majority of cases of unstable angina and NSTEMI. In contrast, plaque rupture and complete thrombotic occlusion of an epicardial coronary artery, with associated transmural infarction, is characteristic of STEMI.[10]

History and physical exam remain the cornerstones of the initial diagnosis and management of ACS. Patients will often present to first responders in the field, who have limited access to medical records. Rapid recognition of this syndrome is crucial for achieving good patient outcomes. Common symptoms of ACS are: Angina (typical) Constant (less than 30 min) and worsened with exertion Often described as substernal, radiating to the abdomen, back, jaw, or upper extremities Improved with nitroglycerine or rest Worsening in quality or quantity from previous anginal episodes Dyspnea Often at rest or with mild exertion Sudden onset or worsening over a short period Diaphoresis Often described as a sudden onset, cold sweat Other nonspecific symptoms Dizziness, abdominal pain, nausea, vomiting, paresthesia, palpitations, and headache Common signs of ACS are: Tachycardia Bradycardia Hypertension Hypotension Hypoxia Tachypnea A new cardiac murmur Orthopnea Lower extremity edema Jugular venous distention Physical exam findings for ACS can vary depending on the patient's presentation and the extent and severity of the disease. In general, a comprehensive physical exam is recommended for all patients presenting with ACS who require catheter-based interventions, with particular attention paid to the cardiovascular, respiratory, neurological, and vascular systems. Due to the need for vascular access, the need for various anticoagulants and antiplatelet medications, and the use of percutaneous equipment, the risk for bleeding and mechanical complications of myocardial infarction must be ruled out before proceeding to the catheterization laboratory. Allergies must be assessed before any catheter-based intervention, and the patient must be sedated throughout the procedure. Patients often will report adverse reactions to many of the medications used for moderate conscious sedation (ie, fentanyl) as well as to medicines administered postprocedure (ie, statins, angiotensin-converting enzyme inhibitors, and others). Additionally, many patients report adverse reactions, allergies, or anaphylaxis to the iodinated contrast used for angiography. Thus, a thorough and detailed history and physical is mandatory before any cardiac catheter-based procedure.

To determine which preprocedure evaluations are needed, one must understand what a cardiac catheterization procedure entails and the complications that can arise from the procedure itself, as well as those that can occur in patients with an ACS. The method involves gaining vascular access and cannulating the coronary arterial tree. Large doses of anticoagulant medications as well as antiplatelet medications will be administered, significantly increasing the bleeding risk of the procedure. Additionally, iodinated contrast is used for imaging in angiographic procedures, most of which are considered nephrotoxic. Other patients can present with a large anterior myocardial infarction or right ventricular infarction that can often present in cardiogenic shock or advanced atrioventricular heart block. A thorough peri-procedural evaluation is vital before sending a patient for cardiac catheterization. Vital Signs The first step for all patients presenting with ACS is to assess for hemodynamic instability. Heart rate should be continuously monitored, along with blood pressure readings every 3 to 5 minutes. Pulse oximetry should be performed on arrival and constantly monitored. The temperature should be taken to assess for fever or other signs of systemic infection. The respiratory rate should be continuously monitored in cases of respiratory distress. 12 Lead Electrocardiogram Generally performed in the emergency room when a patient first presents with ACS. Typical electrocardiogram (ECG) findings for ACS vary based on subtype and presentation. Unstable angina and NSTEMI can present with a normal ECG or with an ECG concerning for ischemia, such as ST depressions, T wave inversion, or sustained or nonsustained arrhythmias (premature ventricular complexes, nonsustained ventricular tachycardia, and sustained ventricular tachycardia, to name a few). STEMI will most commonly present as J-point elevation. Continuous Telemetry Every patient with ACS should have continuous telemetry monitoring, most commonly with a portable cardiac resuscitation device and defibrillation pads, placed before presenting to the cardiac catheterization laboratory. Labs The following labs should be obtained in a patient with suspected ACS: Complete blood count

Continuous Telemetry Every patient with ACS should have continuous telemetry monitoring, most commonly with a portable cardiac resuscitation device and defibrillation pads, placed before presenting to the cardiac catheterization laboratory. Labs The following labs should be obtained in a patient with suspected ACS: Complete blood count Due to the use of high-dose anticoagulant and antiplatelet medications, a complete blood count is necessary to assess baseline hemoglobin and platelet levels, which helps quantify the risk of bleeding. Basic metabolic profile Baseline blood urea nitrogen and creatinine levels are necessary to evaluate for post-procedure contrast nephropathy and to assess the ability to use other cardiac medications that are renally cleared when nephrotoxic agents, specifically iodinated contrast, are used during the procedure. Partial thromboplastin time To assess baseline anticoagulation levels and for appropriate dosing and monitoring of medications during the procedure. Prothrombin time and international normalized ratio These determine baseline anticoagulation levels and ensure proper dosing; therefore, medication monitoring is necessary during the procedure. Troponin To assess the baseline degree of cardiac damage and allow for quantification of the timing of the initial event Creatine kinase-MB Sometimes used to help assess for acute or subacute stent thrombosis in a patient who has recently undergone percutaneous coronary intervention. Brain natriuretic peptide This is generally not needed. However, it can help assess and establish a baseline for treatment and prognosis in patients with congestive heart failure in the setting of acute myocardial infarction. Imaging Chest x-ray Generally not needed, but can assist in assessing for acute pulmonary edema and evidence of cardiogenic shock Computed tomography (CT) chest with contrast Generally not required unless there is a concern for aortic dissection, pulmonary embolism, or other causes of acute chest pain CT brain without contrast Generally not needed unless there is a concern for possible acute ischemic or hemorrhagic CVA Emerging Technology

Generally not needed, but can assist in assessing for acute pulmonary edema and evidence of cardiogenic shock Computed tomography (CT) chest with contrast Generally not required unless there is a concern for aortic dissection, pulmonary embolism, or other causes of acute chest pain CT brain without contrast Generally not needed unless there is a concern for possible acute ischemic or hemorrhagic CVA Emerging Technology Within the spectrum of ACS, a growing field of understanding and recognition of vulnerable plaques is emerging. With the increasing use of intravascular ultrasound (IVUS) assessment, near-infrared IVUS, and noninvasive CT angiography (CTA), the understanding of plaque morphology and vulnerability has emerged as a key area of interest. Data from the PROSPECT Trial provided insight into the use of virtual histology for plaque assessment. From this, we have a better understanding of what makes a plaque vulnerable to an ACS event. Four characteristics have been described: lipid-rich plaque, minimal luminal area less than 4 mm2, a positive remodeling index, and thin-cap fibroatheroma.[11] Additionally, other assessments of plaque vulnerability have been reported in the NIRS IVUS data, including a lipid core burden index exceeding 400.[12]

Approach and Access The approach to acute coronary syndrome is often complex, as each patient can present with different aspects of the spectrum of the disease. This consists of an interprofessional approach often termed as a "heart team approach." This approach typically involves a discussion among multiple healthcare providers regarding their approach to coronary artery disease. From both a surgical and a percutaneous perspective, the approach to ACS can be systematic and safe.[13] Various approaches can be used.[14][15][16][17][18] They include: Transradial Generally preferred for ACS. In this approach, access is gained via the right or left radial artery, with sheath insertion to maintain vascular access. Diagnostic and guiding catheters are then used from this approach for both diagnostic and therapeutic management. The transradial approach has been demonstrated in a large meta-analysis of multiple trials to be safer, with a significantly lower bleeding risk and vascular complications (hematoma formation, pseudoaneurysm formation, and retroperitoneal bleeding) compared to the transfemoral approach. However, the transradial approach is associated with higher radiation exposure to both the patient and the operator compared to a transfemoral approach. Transfemoral Left or right common femoral artery is accessed and sometimes preferred over transradial access because of fewer anatomical variations and the ability for large bore access if needed; however, it is associated with higher rates of major adverse cardiovascular events driven by significant bleeding. This method also correlates with increased mortality in ACS when compared to a transradial approach. Transbrachial This approach is seldom used due to the risk of limb occlusion and compromised vessel patency. Transulnar This is also very rarely used due to the vessel's size, lack of evidence, and limited operator experience. The emerging literature suggests that transulnar can be a viable option if needed. Distal radial access This is rarely used due to the size of the vessel, the lack of randomized controlled trials, and limited operator experience. The emerging literature suggests that the distal left or right radial can be a viable option if needed. Evidence, although limited, supports less radial artery occlusion post-procedure with transradial compared to radial access, as well as improved operator and patient comfort.

This is rarely used due to the size of the vessel, the lack of randomized controlled trials, and limited operator experience. The emerging literature suggests that the distal left or right radial can be a viable option if needed. Evidence, although limited, supports less radial artery occlusion post-procedure with transradial compared to radial access, as well as improved operator and patient comfort. Types of Coronary Wires Coronary wires are generally 0.014 mm in diameter and are introduced to the coronary tree via a guiding catheter. Multiple coronary wires exist—described as "workhorse," "extra supportive," or "hydrophilic," among many other terms beyond the scope of this article. Types of Coronary Catheters The various types of coronary catheters include: Diagnostic catheter Smaller sized (5F–6F) and only used for diagnostic purposes for coronary angiograms and hemodynamic assessment. Guiding catheter Large size (5F–8F)  and used primarily to deliver coronary interventional equipment (ie, coronary wires, balloons, and stent catheters) Balloon catheter (monorail) This type is used for percutaneous balloon angioplasty and is often described by its ability to conform to the vessel. Compliant balloons are useful for lesion predilation and sizing. Noncompliant balloons are frequently used for postdilation to ensure stent apposition and full deployment, or to dilate severely stenotic lesions that are nonresponsive to other therapies. Balloon catheter (over the wire) This is often smaller than the monorail system, and it is generally used for predilation. These catheters can also be used for wire exchanges, medication injection, delivery to the distal coronary bed, and extra guide and wire support. Stenting catheter A stent (bare-metal or drug-eluting) mounted on a balloon is inserted via a monorail system and used for percutaneous coronary intervention. Adjunctive Catheter Therapy Multiple other adjunctive catheter therapies exist; however, they are beyond the scope of this document and are not discussed in detail. Some examples of these therapies are listed below: Thrombectomy catheter This catheter is used to aspirate thrombus during ACS. Atherectomy catheter

A stent (bare-metal or drug-eluting) mounted on a balloon is inserted via a monorail system and used for percutaneous coronary intervention. Adjunctive Catheter Therapy Multiple other adjunctive catheter therapies exist; however, they are beyond the scope of this document and are not discussed in detail. Some examples of these therapies are listed below: Thrombectomy catheter This catheter is used to aspirate thrombus during ACS. Atherectomy catheter This type is used for plaque debulking before angioplasty and stenting. However, multiple atherectomy technologies beyond the scope of this document are not discussed in detail. These are but are not limited to rotation, orbital, laser, and excisional atherectomy. Intravascular ultrasound This imaging catheter allows deep penetration of vascular tissue with ultrasound within the coronary tree. This type is often used to visualize and assess target vessels both before and after intervention. Further description of this device is beyond the scope of this document. Optical coherence tomography catheter Similar to intravascular ultrasound, this catheter is used for intravascular imaging with light waves, providing excellent spatial resolution within the coronary vasculature. Excellent visualization within the vessel lumen for assessment of intraluminal irregularities such as dissection, stent thrombosis, among others. Further description of this device is beyond the scope of this document. Scoring balloon catheters These devices are also known as cutting balloons. Their predominant use is for balloon angioplasty of severely diseased, calcified lesions, where balloon slippage is an issue. These devices are also helpful in areas of in-stent restenosis. Distal embolization device A wire "basket" device, which is placed distally in the target vessel in cases in which distal embolization of vascular debris (ie, atheroma, thrombus) is expected to avoid the no-reflow phenomenon. Most commonly indicated in cases involving atherectomy or saphenous vein graft interventions. Guideliner This is a coaxial guiding catheter extension delivered to the target vessel over a guidewire monorail system. This device is helpful in cases where guide support due to guide catheter seating is an issue. Support, micro, and crossing catheters

A wire "basket" device, which is placed distally in the target vessel in cases in which distal embolization of vascular debris (ie, atheroma, thrombus) is expected to avoid the no-reflow phenomenon. Most commonly indicated in cases involving atherectomy or saphenous vein graft interventions. Guideliner This is a coaxial guiding catheter extension delivered to the target vessel over a guidewire monorail system. This device is helpful in cases where guide support due to guide catheter seating is an issue. Support, micro, and crossing catheters These are small catheters that can be inserted into a guiding catheter via an over-the-wire system to assist in crossing complex, often chronic, total occlusions in the coronary and peripheral vascular trees. Mechanical Support Devices Mechanical support catheters and therapies exist; however, these are beyond the scope of this document and are not discussed in detail. These are but are not limited to intraaortic balloon pump counterpulsation therapy, ventricular support devices, tandem heart support devices, and extracorporeal membrane oxygenation.[19][20]

Six-month mortality rates recorded in the Global Registry of Acute Coronary Events (GRACE) for patients with STEMI were estimated close to 17%, 13% for patients with NSTEMI ACS, and 8% for those with unstable angina. These numbers have continued to decline as percutaneous coronary intervention (PCI) evolves and operator experience increases. Additionally, the broad adoption of transradial PCI has continued the trend of decreasing mortality in both NSTEMI and STEMI. The results of the MATRIX, STEMI-RADIAL, and numerous other studies over the past decade support this adoption.

Complications arising from coronary intervention can range from minor to major, depending on their hemodynamic significance. The most common complication of coronary intervention is access site bleeding. Due to a large volume of anticoagulation and the occasional need for large-bore access, access-site complications (hematomas, pseudoaneurysms, dissections, among others) can occur, most commonly with transfemoral access. Additional complications seen are contrast-induced nephropathy, vessel dissection or perforation, acute cerebrovascular accident or other embolic phenomena, myocardial infarction, need for emergent cardiothoracic surgery, and rarely death. The rates of complications vary by center and operator volume; however, for the most part, the risk of the procedure is generally low (between 1%–2%), and the benefits of the procedure far outweigh the risks.[21]

Deterrence in the context of ACS catheter interventions primarily focuses on preventing the progression to coronary occlusion and reducing the need for emergent PCI. Primary prevention strategies include aggressive risk factor modification—encouraging patients to stop smoking, adhere to a heart-healthy diet (low in saturated fat and high in fruits, vegetables, and whole grains), maintain a healthy weight, and engage in regular aerobic exercise. Control of hypertension, diabetes, and dyslipidemia through pharmacologic and lifestyle interventions is also essential. Secondary prevention focuses on preventing recurrent ischemic events following an ACS or PCI. This includes strict adherence to antiplatelet therapy (dual antiplatelet therapy for the recommended duration), lipid-lowering therapy (typically high-intensity statins), beta blockers, angiotensin-converting enzyme inhibitors, or angiotensin II receptor blockers, and other guideline-directed medical therapies. Patient education should emphasize medication adherence, recognition of early ischemic symptoms, and the importance of follow-up care, as premature discontinuation of antiplatelet agents significantly increases the risk of stent thrombosis and recurrent myocardial infarction. Patient education is a critical component of improving outcomes following ACS and catheter-based interventions. Before and after PCI, patients should receive clear explanations about the nature of their disease, the purpose and risks of coronary catheterization, and the importance of post-procedure care. Education should include recognizing warning signs of restenosis or recurrent ischemia—such as chest pain, dyspnea, or syncope—and understanding when to seek emergent medical attention.

Patient education is a critical component of improving outcomes following ACS and catheter-based interventions. Before and after PCI, patients should receive clear explanations about the nature of their disease, the purpose and risks of coronary catheterization, and the importance of post-procedure care. Education should include recognizing warning signs of restenosis or recurrent ischemia—such as chest pain, dyspnea, or syncope—and understanding when to seek emergent medical attention. Patients should also be informed about post-procedure activity restrictions (such as avoiding heavy lifting for several days), wound care at the catheter insertion site, and how to manage potential complications, such as bleeding or hematoma. In the long term, comprehensive cardiac rehabilitation programs should be encouraged to enhance functional recovery, promote lifestyle modifications, and reinforce adherence to medication. Ultimately, deterrence and patient education work synergistically: when patients understand both the immediate and long-term implications of their coronary disease and interventions, adherence improves, complications decrease, and recurrent events are minimized. The procedure itself is described to the patient as follows: "A cardiac catheterization is a minimally invasive procedure in which we will be assessing the blood vessels of your heart with the use of contrast dye and fluoroscopy. The first step of the procedure involves gaining vascular access, most commonly through the radial artery in the wrist and, less commonly, through the femoral artery in the groin. Once arterial access is obtained, we will use a small catheter (approximately 2–3 mm in diameter) and a wire (approximately 0.014–0.035 mm in diameter) to access the heart's arteries. Once the arteries are accessed, we will take multiple images to identify significant blockages. If blockages are present, we will proceed with fixing these lesions with stents and balloons. The procedure carries risks of bleeding and infection at the entry site, pain, discomfort, vascular complications, stroke, heart attack, and possible death. The risk is generally low (between 1%–2%), and the benefits of the procedure far outweigh the risk." Patient education and understanding of the procedure and risks remain a foundational piece of a successful intervention.[23]

Effective care for patients undergoing ACS catheter interventions requires a coordinated, multidisciplinary approach centered on timely care, patient safety, and optimized outcomes. Advanced clinicians lead diagnostic evaluations, risk stratification, and the rapid activation of the cardiac catheterization team to minimize door-to-balloon times. Skilled interventional cardiologists perform PCI with precision, while advanced clinicians and nurses ensure preprocedure stabilization, continuous hemodynamic monitoring, and postprocedure recovery care. Nurses play a vital role in patient assessment, education, and early recognition of complications such as bleeding, arrhythmias, or recurrent ischemia. Pharmacists contribute by carefully managing antiplatelet, anticoagulant, and adjunctive therapies, verifying dosing accuracy, monitoring for drug interactions, and reinforcing adherence to dual antiplatelet therapy—an essential component of secondary prevention. Interprofessional communication and care coordination are critical throughout the continuum of ACS management. Efficient handoffs among emergency medicine, cardiology, nursing, pharmacy, and critical care teams ensure continuity and safety during the acute phase and during the transition to post-procedural care. Structured communication tools, such as SBAR (situation, background, assessment, and recommendation) and standardized ACS protocols, enhance clarity and reduce errors. After discharge, collaboration with primary care clinicians, cardiac rehabilitation specialists, and dietitians supports the modification of risk factors and long-term recovery. A patient-centered strategy—emphasizing education, shared decision-making, and psychosocial support—empowers patients to actively participate in their care, improving adherence and reducing readmission rates. Through coordinated teamwork and effective communication, healthcare professionals collectively enhance the quality, safety, and efficiency of care for patients undergoing ACS catheter interventions.